Is Novo Nordisk Stock a Buy Now?
Two years ago, Novo Nordisk (NYSE: NVO), a Denmark-based pharmaceutical company, was performing so well that it was positively affecting the economy of its home country. However, the past 18 months have been very different. Novo Nordisk's shares have declined substantially over this period, losing 58% of their value.
With several potential catalysts on the horizon, however, Novo Nordisk is looking to bounce back from its recent woes. Can the company pull it off? Let's find out whether it's worth investing in the stock today.
Through the first half of the year, Novo Nordisk recorded net sales of 154.9 billion Danish kroner ($24.4 billion), 15% higher than the comparable period of the previous fiscal year. Almost 94% of that total came from its diabetes or weight management products, especially the best-known ones, Ozempic and Wegovy.
Source Fool.com
